Document Security Systems (DSS) Stock Runs On COVID-19 News

Document Security Systems DSS Stock News

Document Security Systems, Inc. (NYSEAMERICAN: DSS) is making a run for the top in the market this morning, trading on gains of nearly 50% early on. The gains come after the company announced that its acquisition target released positive COVID-19 data. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

DSS Stock Rockets On COVID-19 News

In the press release, Document Security Systems said that its acquisition target, Impact Biomedical, published results from the laboratory. In the lab, the company tsted in-vitro Equivir and Linebacker, the compay’s proprietary compounds, along with 3F Biofragrance againced COVID-19.

These compounds were tested with SARS-CoV-2, demonstrating in-vitro success as a treatment. DSS also said that there was success in these compounds as prophylactics, protecting cells from infection by the virus.

Moreover, 3F Biofragrance proved to be succssful as a surface disinfectant. The product killed the virus in concentrations as low as 1/5000 after 15 seconds of testing.

DSS went on to explain that Impact designed and patented Equivir as a prophylactic to be deployed lik a vitamin. The drug works by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells.

In a statement, Mr. Chan Heng Fai, Chairman at DSS, had the following to offer:

We are pleased with the in-vitro results of Impact Biomedical’s two lead compounds and their potential as a treatment, as well as a prophylactic, in the fight against COVID-19. We continue to progress toward our goal of completing the acquisition and look forward to providing further updates as additional milestones are achieved.

This News Is Great

All in all, the news released by Document Security Systems was overwhelmingly positive. After all, the company is currently in the process of acquiring Impact. With the news today, the portfolio at Impact is worth well over $900 million. However, the company is paying a small fraction of this value for the acquisition, giving investors plenty of reasons to be excited about DSS stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.